Compare Adaptive Biotechnologies Corp (ADPT) vs ARK Autonomous Technology & Robotics ETF (ARKQ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs ARK Autonomous Technology & Robotics ETF — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while ARK Autonomous Technology & Robotics ETF trades at $123.81. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, ARK Autonomous Technology & Robotics ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | ARKQ | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | Sector/Thematic |
52-Week High | $22.37 | $143.82 |
52-Week Low | $10.24 | $88.47 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
ARKQ trades at $130.11, up 1.7% on the day, with a bearish technical signal from moving averages and neutral oscillators. The ETF focuses on autonomous technology and robotics, benefiting from AI momentum, with assets under management reaching $2.7 billion as of April 2026 (Seeking Alpha, 2026-04-26). Recent news highlights sector growth in AI, robotics, and autonomous vehicles, though valuation metrics like P/E are not provided in the current data.
Outlook remains tied to AI and robotics adoption, with potential from themes like humanoid robots and autonomous driving. Risks include high valuations, sector volatility, and reliance on tech spending. Analyst sentiment is mixed, with some upgrades citing growth potential but technical indicators suggesting near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About ARK Autonomous Technology & Robotics ETF
ARKQ is an actively managed ETF that invests in autonomous technology and robotics. It focuses on disruptive innovations like autonomous mobility, electric vehicles, 3D printing, and energy storage, with holdings such as Tesla and Teradyne.
Read more on ARKQ →
